Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Abatacept Conversion in Kidney Transplant Recipients Receiving Belatacept
NCT04955366Phase 2Completed
- Sponsor
- Emory University
- Start
- Sep 2021
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abatacept in renal transplant rejection (RTR) (2 arms), sponsored by Emory University. Primary endpoint: Change in mean estimated Glomerular Filtration Rate at 12 months. Started Sep 2021; status: completed.
02
Drugs
abatacept
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT04955366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955366.